IL-33 induces IL-13 production by mouse mast cells independently of IgE-FcεRI signals
The IL‐1‐related molecules, IL‐1 and IL‐18, can promote Th2 cytokine production by IgE/antigen‐FcεRI‐stimulated mouse mast cells. Another IL‐1‐related molecule, IL‐33, was identified recently as a ligand for T1/ST2. Although mouse mast cells constitutively express ST2, the effects of IL‐33 on mast c...
Gespeichert in:
Veröffentlicht in: | Journal of leukocyte biology 2007-12, Vol.82 (6), p.1481-1490 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The IL‐1‐related molecules, IL‐1 and IL‐18, can promote Th2 cytokine production by IgE/antigen‐FcεRI‐stimulated mouse mast cells. Another IL‐1‐related molecule, IL‐33, was identified recently as a ligand for T1/ST2. Although mouse mast cells constitutively express ST2, the effects of IL‐33 on mast cell function are poorly understood. We found that IL‐33, but not IL‐1β or IL‐18, induced IL‐13 and IL‐6 production by mouse bone marrow‐derived, cultured mast cells (BMCMCs) independently of IgE. In BMCMCs incubated with the potently cytokinergic SPE‐7 IgE without specific antigen, IL‐33, IL‐1β, and IL‐18 each promoted IL‐13 and IL‐6 production, but the effects of IL‐33 were more potent than those of IL‐1β or IL‐18. IL‐33 promoted cytokine production via a MyD88‐dependent but Toll/IL‐1R domain‐containing adaptor‐inducing IFN‐β‐independent pathway. By contrast, IL‐33 neither induced nor enhanced mast cell degranulation. At 200 ng/ml, IL‐33 prolonged mast cell survival in the absence of IgE and impaired survival in the presence of SPE‐7 IgE, whereas at 100 ng/ml, IL‐33 had no effect on mast cell survival in the absence of IgE and reduced mast cell survival in the presence of IgE. These observations suggest potential roles for IL‐33 in mast cell‐ and Th2 cytokine‐associated immune responses and disorders. |
---|---|
ISSN: | 0741-5400 1938-3673 |
DOI: | 10.1189/jlb.0407200 |